EP4168806A2 - Procédés et utilisations associées, kits et système d'évaluation de la septicémie - Google Patents

Procédés et utilisations associées, kits et système d'évaluation de la septicémie

Info

Publication number
EP4168806A2
EP4168806A2 EP21736646.7A EP21736646A EP4168806A2 EP 4168806 A2 EP4168806 A2 EP 4168806A2 EP 21736646 A EP21736646 A EP 21736646A EP 4168806 A2 EP4168806 A2 EP 4168806A2
Authority
EP
European Patent Office
Prior art keywords
sepsis
patient
protein
biomarkers
biomarker signature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21736646.7A
Other languages
German (de)
English (en)
Inventor
Thomas Robert LAWS
Roman Antoni Lukaszewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Defence filed Critical UK Secretary of State for Defence
Publication of EP4168806A2 publication Critical patent/EP4168806A2/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the invention relates to protein biomarkers representing protein biomarker signatures to assess a patient who may develop sepsis, or who may have developed sepsis.
  • the invention relates in particular to methods to assess whether a patient may develop sepsis or to diagnose a patient as having sepsis, monitoring a patient to predict whether and when the patient may develop sepsis, or to monitor the progression of sepsis in the patient, monitoring the responsiveness of a patient to treatment with an antimicrobial agent(s) and/or immunosuppressive agent(s), or selecting a therapeutic agent(s) and/or immunosuppressive agent(s) for administration to a patient predicted or diagnosed as having sepsis.
  • the invention also relates to use of protein biomarkers representing protein biomarker signatures for sepsis, and kits and systems for assessing or monitoring a patient to predict or diagnose sepsis, the response of the patient to treatment for sepsis, or selecting a therapeutic agent(s) and/or immunosuppressive agent(s) for treatment of sepsis.
  • sepsis is a challenging condition to resolve on account of factors including: the often rapid onset of disease requiring a similarly timely diagnosis and/or administration of appropriate medical intervention protocols; a lack of a validated, standard diagnostic test; the variety of clinical presentation(s) often complicating diagnosis; the range of infectious agents capable of causing sepsis; and the difficulty in identifying the infectious agent in question, increasing the likelihood of an initial wide-spectrum antimicrobial agent(s) selection not providing optimal or effective treatment.
  • patient symptoms can initially present as non-specific to sepsis, there is the potential for clinicians to administer treatment with incorrect or non-optimal antimicrobial regimens, risking contributing to the on-going antimicrobial resistance crisis. Indeed, once symptoms appear, there is an inverse correlation between effectiveness of treatment and patient outcome.
  • Sepsis was initially defined in 1991 as a host’s Systemic Inflammatory Response Syndrome (SIRS) to infection (‘Sepsis-1’), identified by clinical parameters based on two or more of temperature level, heat rate, respiratory rate or white blood cell count. More significant incidences, which included organ failure, were considered severe sepsis. Revision of the sepsis and severe sepsis definitions in 2001 were based on the inclusion of further clinical parameters, which may evidence infection in a host (‘Sepsis-2’).
  • SIRS Systemic Inflammatory Response Syndrome
  • qSOFA quickSOFA
  • septic shock was defined as ‘a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality’. Efforts to standardise the definition of sepsis provides greater clarity for clinicians when establishing, and initiating treatment against, incidences of sepsis.
  • the invention provides a method for analysing a biological sample, obtained from a patient, to assess whether the patient may develop sepsis or to diagnose the patient as having sepsis, the method comprising the steps of: a. determining in the biological sample individual levels of protein biomarkers representing a protein biomarker signature; and b.
  • the protein biomarkers of the protein biomarker signature comprises at least four biomarkers from a list consisting of CCL-16, CD28, CD244, FGF21 , GALNT3, GT, IL-18BP, JAM-A, LDL-R, LILRB5, LTBR, MCP-2, MMP-1 , NUCB2, SIGLEC10, TNF- R1, TNF-R2, TNFRSF10A, TNFRSF11A, TNFRSF14, TRAILR2 and UPAR.
  • biological sample includes, but not exclusively, blood, serum, plasma, urine, saliva, cerebrospinal fluid or any other form of material, preferably fluid-based or capable of being converted into a fluid-like state (e.g. tissue which can be broken down or separated in a solution, such as a buffered solution), which can be extracted or collected from a patient.
  • a fluid-like state e.g. tissue which can be broken down or separated in a solution, such as a buffered solution
  • sepsis is understood to refer to sepsis in accordance with the Sepsis-3 definition described above.
  • biomarker signature a biomarker signature
  • PCR Polymerase Chain Reaction
  • the Applicant has identified, through a comprehensive analysis of carefully characterised host samples (i.e. characterised according to the Sepsis-3 definition), a 22-protein panel of biomarkers highly significant to predicting sepsis i.e. an ability to predict infection and organ dysfunction. From this 22-protein panel, the Applicant has identified a series of protein combinations that represent biomarker signatures capable of predicting sepsis, offering mean Area Under The Curve (AUC) values greater than 0.72, with one exemplified protein biomarker signature having an AUC of 0.86 at Day -1 prior to clinical diagnosis of sepsis.
  • AUC Area Under The Curve
  • biomarker signatures can offer a high level of confidence for pre-condition diagnosis for sepsis involving organ dysfunction as a consequence of infection and overwhelming immune dysregulation.
  • biomarker signatures also offer a mean AUC of greater than 0.72 for providing confirmatory diagnosis of sepsis, with one exemplified protein biomarker signature having an AUC of 0.87 i.e. a high level of confidence for biomarker signatures providing a confirmatory diagnosis.
  • the subsets identified by the Applicant offer a manageable number of protein targets in a protein biomarker signature, e.g. having 4- 10 proteins, thus being suitable for transitioning onto current protein diagnostic platform technologies.
  • the 22 proteins identified are summarised below in Table 1. Information regarding each protein can be found at www.uniprot.org/ (see ‘Uniprot reference’ column, which provides the corresponding Uniprot Accession Number reference for each protein, which enables access to information including each protein’s sequence).
  • Table 1 A summary of the 22 proteins found to be highly significant in predicting Sepsis-3 Assuring confidence in the classification of patient condition is a key task for any study that is reliant on clinical opinion to baseline data used in subsequent analytical techniques. Any errors of clinical judgement in identifying sepsis in the study cohort is likely to have a substantial impact on the performance of statistical models produced following analysis of patient samples.
  • a key advantage of the clinical study underpinning the Applicant’s research is the involvement of clinical experts in the field of sepsis, who have retrospectively reviewed patient data to agree on an accurate day of diagnosis according to the Sepsis-3 definition.
  • the Applicant conducted studies that measured 718 protein analytes in subject samples obtained from the wide-ranging clinical study that carefully categorised each patient according to either a) diagnosis of sepsis according to the Sepsis-3 definition, b) control (i.e. no specific pathology) or c) Systemic Inflammatory Response Syndrome (‘SIRS’ i.e. a non-specific inflammation response in a host without an adjudication of infection). Both the control and SIRS samples were used as comparator controls in the identification of sepsis-relevant biomarkers. Comparative statistical analysis of the protein abundance between comparators and patients who went on to develop sepsis led to the identification of small subsets e.g. combinations of between two and ten protein biomarkers, in particular between four and ten proteins, from a list of 22 identified proteins, which provide a high diagnostic capacity to estimate a patient’s risk of developing sepsis.
  • SIRS Systemic Inflammatory Response Syndrome
  • the statistical analysis for identifying protein biomarker sets comprised the following steps. Firstly, all proteins that had little or no differential abundance across the three sample categories (sepsis; control; SIRS) were eliminated, with remaining proteins taken on to the next steps in the analysis. This elimination was achieved by setting upper and lower thresholds of abundance for the control patient’s proteins. The numbers of sepsis patients (samples) with abundances for the same proteins being outside of these upper and lower limits were then deemed more likely to have predictive potential, and thus retained in the analysis, with all other proteins (having a similar abundance between the upper and lower limit) being disregarded. Secondly, a further down-select was applied to find a manageable numbers of proteins for a diagnostic system.
  • pansepsis diagnostic i.e. a diagnostic capable of diagnosing sepsis resulting from infection by different infectious agents (e.g. sepsis resulting from bacterial infection, sepsis resulting from viral infection etc.).
  • the Applicant’s approach instead was to find the protein analytes whose abundance was least related within the down-selected list, to select the diagnostic proteins for all prevalent forms of Sepsis-3. These smaller subsets were evaluated for predictive potential using neurological networks.
  • the Applicant’s approach differs from traditional down-selection methods where a hypothesis test is used and only statistically significant proteins are included.
  • the rational for deviating from these methods is that the patient population has substantial heterogeneity and are not made of defined groups.
  • sepsis will include a variety of primary loci of infection and disease (i.e. pneumonia, meningitis etc.) and potentially a variety of different pathogens, whereas the SIRs may be a result of “sterile inflammation” or even auto-immunity.
  • This can mean that the data can take bimodal forms where some sepsis individuals have altered abundance and some not.
  • This ‘hidden’ aspect of the data prevents accurate hypothesis testing.
  • a second reason to deviate from hypothesis tests is that the Applicant has used a very accurate assay system for estimating relative concentrations of proteins across populations.
  • biomarker signatures A-V 22 specific biomarker signatures (summarised in Table 3; biomarker signatures A-V) were elucidated that provide combinations of from 2 to 10 biomarkers capable of pre-condition diagnosis (denoted as Day -1 i.e. one day before sepsis diagnosis), and confirmatory diagnosis (denoted as Day 0 i.e. day of sepsis diagnosis), of sepsis in subjects.
  • 20 biomarker signatures comprising at least four biomarkers from the 22-protein list (biomarker signatures A-G, and J-V) were identified for incorporation in the methods of the invention, and the corresponding uses, kits and systems, as described as follows.
  • the protein biomarkers of the protein biomarker signature comprises at least four biomarkers, at least five biomarkers, at least six biomarkers, at least seven biomarkers, at least eight biomarkers, at least nine biomarkers or at least ten biomarkers from a list consisting of CCL-16, CD28, CD244, FGF21 , GALNT3, GT, IL- 18BP, JAM-A, LDL-R, LILRB5, LTBR, MCP-2, MMP-1, NUCB2, SIGLEC10, TNF-R1, TNF-R2, TNFRSF10A, TNFRSF11A, TNFRSF14, TRAILR2 and UPAR
  • the protein biomarker signature comprises CCL-16 and MCP-2. These biomarkers were shown to be common to 15 of the 20 preferred biomarker signatures (A-B, J-V). Furthermore, these biomarkers are included in those biomarker signatures shown to have the highest performance with respect to predicative efficacy (biomarker signature N (mean AUC of 0.86 for both Days -1 and 0 respectively); biomarker signature A (mean AUC of 0.80 and 0.86 at Days -1 and 0 respectively)). Indeed, all 15 biomarker signatures had an AUC of greater than 0.81 at Day 0.
  • the protein biomarker signature comprises or consists of LTBR, CCL16, CD28, FGF21 and MCP-2.
  • the specific 5-protein biomarker signature (J) offered a mean AUC of 0.76 at Day -1 and 0.87 at Day 0, thus in particular providing the strongest confirmatory diagnosis of sepsis while using a relatively small number of proteins, thus being especially advantageous in terms of being suitable for integration onto a diagnostic protein platform.
  • the protein biomarker signature further comprises GALNT3, GT, LDL-R, LILRB5 and MMP-1.
  • This biomarker combination i.e. also comprising at least CCL-16 and MCP-2, represented 14 of the 20 identified biomarker signatures (including biomarker signatures A and N). All mean AUCs for these biomarker signatures were greater than 0 81 at Day 0, again offering a positive confirmatory diagnosis of sepsis.
  • the protein biomarker signature further comprises FGF21.
  • This biomarker combination i.e. also comprising at least CCL-16, MCP-2, GALNT3, GT, LDL-R, LILRB5 and MMP-1 represented 13 of the 20 identified biomarker signatures (including biomarker signatures A and N), supporting the view that a key subset of biomarkers exists from the 22-identified proteins that can form the basis for precondition/confirmatory diagnosis of sepsis.
  • the protein biomarker signature comprises or consists of CCL16, CD28, FGF21 , GALNT3, GT, LDL-R, LILRB5, MCP-2, MMP-1 and TNFRSF11A.
  • This particular biomarker signature (N) provided the highest predictive efficacy at Day -1 across the 20 biomarker subsets with a mean AUC of 0.86, and the joint-second highest performing mean AUC at Day 0 (0.86).
  • This biomarker signature therefore represents a particularly attractive option in terms of pre-condition and/or confirmatory diagnosis of Sepsis-3.
  • the protein biomarker signature comprises or consists of CCL16, CD244, FGF21 , GALNT3, GT, LDL-R, LILRB5, MCP-2, MMP-1 and TNF-R1.
  • This particular biomarker signature (K) provided the second highest predictive efficacy at Day -1 , with a mean AUC of 0.81 . Furthermore, this biomarker signature provided a mean AUC of 0.87 at Day 0.
  • the protein biomarker signature comprises or consists of CCL16, CD28, FGF21 , GALNT3, GT, LDL-R, LILRB5, MCP-2, MMP-1 and TNF-R1 .
  • This particular biomarker signature (A) provided high performing mean AUCs at Days -1 and 0, reporting values of 0.80 and 0.86 respectively.
  • the protein biomarker signature comprises or consists of CCL16, CD28, FGF21 , GALNT3, GT, LDL-R, LILRB5, MCP-2, MMP-1 and U-PAR.
  • this particular biomarker signature (V) also provided mean AUCs at Days -1 and 0 of 0.80 and 0.86 respectively.
  • the protein biomarker signature comprises or consists of CCL16, CD28, FGF21 , GALNT3, GT, LDL-R, LILRB5, MCP-2, MMP-1 and TRAIL-R2.
  • This particular biomarker signature (M) provided mean AUCs at Days -1 and 0, reporting values of 0.78 and 0.85 respectively.
  • the protein biomarker signature further comprises at least one additional biomarker taken from a list of biomarkers categorised as pro-inflammatory cytokines, anti-inflammatory cytokines, chemokines, acute phase reactants, cell receptors/mediators or vascular markers.
  • additional biomarker taken from a list of biomarkers categorised as pro-inflammatory cytokines, anti-inflammatory cytokines, chemokines, acute phase reactants, cell receptors/mediators or vascular markers.
  • the protein biomarker signature further comprises at least one additional biomarker from a list consisting of procalcitonin (PCT), lactate, C-reactive protein (CRP), D-Dimer and pancreatic stone protein (PSP).
  • PCT procalcitonin
  • CRP C-reactive protein
  • PSP pancreatic stone protein
  • the invention provides a method for analysing biological samples, obtained from a patient at risk of, or having developed, sepsis, to monitor the patient, the method comprising the steps of: a. determining in the biological samples, obtained from the patient at a plurality of time points, individual levels of protein biomarkers representing a protein biomarker signature, wherein the protein biomarker signature comprises the biomarkers selected according to the first aspect; and b. using changes in the individual levels of the protein biomarkers collectively, across the plurality of time points, to monitor the patient and to predict whether the patient may develop sepsis, or to monitor the progression of sepsis in the patient.
  • This aspect is particularly beneficial in identifying patients whose condition with respect to sepsis, i.e. infection and organ dysfunction, is worsening or indeed improving. For example, observing continued/increasing changes in the biomarkers comprising the biomarker signature likely indicates that a patient is still, or is increasingly, septic, suffering organ dysfunction and/or hosting an infective agent as reflected by continued host biomarker dysregulation. Such findings may change patient management strategy and result in a decision to administer an (alternative) antimicrobial regimen and/or other supportive therapies e.g. administration of an immunosuppressive agent(s).
  • biomarkers in the biomarker signature returning to, or achieving levels comparable with, non-sepsis control levels, likely indicates an improvement in a patient’s health status.
  • a currently administered treatment e.g. antimicrobial agent, supportive therapies such as an immunosuppressive agent
  • the method could be implemented at regular time periods e.g. at least once an hour, once every two hours, once every six hours, to monitor a patient.
  • the invention provides a method for analysing biological samples, obtained from a patient predicted or diagnosed as having sepsis, to monitor the responsiveness of the patient to treatment with an antimicrobial agent(s) and/or immunosuppressive agent(s), the method comprising the steps of: a. determining in a sample, obtained from the patient at a plurality of time points, individual levels of biomarkers representing a protein biomarker signature, wherein the protein biomarker signature comprises the biomarkers selected according to the first aspect; and b. using changes in the individual levels of the biomarkers collectively, across the plurality of time points, to monitor the responsiveness of a patient to treatment with an antimicrobial agent(s) and/or immunosuppressive agent(s).
  • This aspect is particularly beneficial in identifying when a course of antimicrobial agent(s) and/or immunosuppressive agent(s), administered by a clinician, may be ineffective, or indeed effective, in terms of eradicating the causative agent of sepsis. For example, observing continued/increasing changes in the biomarkers comprising the biomarker signature likely indicates that a patient is still, or increasingly, septic, suffering organ dysfunction and/or hosting an infective agent as reflected by continued host biomarker dysregulation, as a consequence of a non-optimal antimicrobial and/or immunosuppressive regimen being administered.
  • This scenario may be particularly relevant when a positive identification of a causative agent and/or its levels of antimicrobial susceptibility are yet to be reported by a pathology laboratory. Applying this particular method may aid the decision to administer an alternative antimicrobial and/or immunosuppressive regime. Conversely, levels of biomarkers in the biomarker signature returning to, or achieving levels comparable with, non-sepsis control levels, likely indicates an improvement in a patient’s health status. Such findings may indicate that a currently administered treatment is proving effective.
  • the method could be implemented at regular time periods e.g. at least once an hour, once every two hours, once every six hours, to monitor the responsiveness of the patient to treatment with an antimicrobial agent(s) and/or immunosuppressive agent(s).
  • the invention provides a method for selecting a therapeutic agent(s) and/or immunosuppressive agent(s) for administration to a patient predicted or diagnosed as having sepsis, the method comprising the steps of: a. determining in a sample, obtained from the patient at a time point or plurality of time points, individual levels of biomarkers representing a protein biomarker signature, wherein the protein biomarker signature comprises the biomarkers selected according to the first aspect; and b. using the individual levels of the biomarkers, or the changes in the individual levels of the biomarkers collectively across the plurality of time points, to select a therapeutic agent(s) and/or immunosuppressive agent(s).
  • This aspect is particularly beneficial in identifying an antimicrobial agent(s) and/or immunosuppressive agent(s) for administration by a clinician to a patient for the purpose of eradicating the causative agent of sepsis. For example, observing certain biomarker levels in a sample, or continued/increasing changes in the biomarkers comprising the biomarker signature in samples taken at a plurality of time points, may help inform the selection of certain antimicrobial agent(s) and/or immunosuppressive agents(s). This scenario may be particularly relevant when a positive identification of a causative agent and/or its levels of antimicrobial susceptibility are yet to be reported by a pathology laboratory.
  • Applying this particular method may aid the decision to administer a certain antimicrobial and/or immunosuppressive regime.
  • levels of biomarkers in the biomarker signature returning to, or achieving levels comparable with, non-sepsis control levels likely indicates an improvement in a patient’s health status.
  • Such findings may indicate that a currently administered treatment is proving effective.
  • the method could be implemented at regular time periods e.g. at least once an hour, once every two hours, once every six hours, to inform on the identification of an antimicrobial agent(s) and/or immunosuppressive agent(s).
  • the invention provides use of protein biomarkers representing a protein biomarker signature for sepsis, wherein the protein biomarker signature comprises the biomarkers selected according to the first aspect.
  • the invention provides a kit for implementing at least step a) of the first aspect, second aspect, third aspect or fourth aspect, wherein the kit comprises a labelled reagent or a plurality of labelled reagents for detecting individual levels of each protein biomarker in a protein biomarker signature, in at least one sample taken from the patient, wherein the labelled reagent or reagents is/are capable of binding specifically to each protein biomarker selected according to the first aspect.
  • labelled reagent may refer to an element capable of specifically binding to at least one of the proteins in a protein biomarker signature according to the present invention, wherein the element may be linked or associated with a labelling means that allows for identification of the presence of the protein.
  • the kit provides a plurality of elements, each of which is specific for one of the protein biomarkers in the protein biomarker signature. During use of the kit by a user, a binding event between such an element and its target protein is determined by detecting the labelling means.
  • the element(s) may be a biomolecule such as a protein, capable of binding to at least a region (i.e. a particular sequence or epitope) of its intended target protein of the biomarker signature.
  • the labelled reagent(s) is/are antibody-based. Further preferably, the labelled reagent(s) is/are based on monoclonal antibodies. Antibodies are well established as capture means for target proteins, and can be reliably produced using known methodologies for inclusion in kits or systems. Furthermore, procedures exist for labelling antibodies with means capable of detection.
  • the labelling of the reagents can be achieved by a variety of ways as would be understood by the skilled person.
  • fluorescent, chromogenic, coloured or magnetic labels can be used.
  • One common approach is the use of conjugated gold, carbon or coloured latex nanoparticles, which allow visualisation of binding/capture events between the labelled reagent and a target protein analyte.
  • fluorescent or magnetic labels can require the use of a specific detector to assess whether binding events have taken place based on wavelength or magnetic signal respectively. Such detection means, whether visual or otherwise, are typically capable of quantitative measurement based on the intensity of the label.
  • Measuring the intensity for example by a specific visual reader, such as a camera or reader, or a non-visual detector in the case of magnetic-based labels, can enable the conversion of the label intensity into a corresponding protein analyte level or concentration.
  • the label intensity specific for each protein biomarker determines the individual level of each protein biomarker in the protein biomarker signature, in a sample, which in turn provides an assessment of infection and/or organ dysfunction and/or sepsis.
  • the reagents are labelled with gold nanoshells.
  • Gold nanoshells consist of a 120 nm silica core coated with a 15 nm thick gold shell, and are capable of providing an increase in sensitivity relative to gold nanoparticles e.g. a 20 times increased in sensitivity. Due to the plasmon resonance of gold nanoshells, an intense blue line will be visible on white lateral flow test strips.
  • the kit according to the sixth aspect further comprises a test element to which the labelled reagents are, or are capable of being, incorporated or applied.
  • the test element is a lateral flow device (LFD).
  • LFD lateral flow device
  • Such devices are well known in the art and are in particular capable of detecting the presence of an analyte(s) in a sample, such as protein biomarkers of a protein biomarker signature in a biological sample.
  • LFDs are well suited as point-of-care devices due to their speed of testing, versatility and ease-of-use, requiring little in the way of specialist users or complex training.
  • LFDs comprise a membrane strip to which can be applied a liquid sample potentially containing a protein analyte(s) of interest.
  • a biological sample e.g. an antibody conjugate
  • the sample flows along the membrane and encounters labelled reagent(s) (e.g. an antibody conjugate) specific for a protein analyte(s) of interest. If the protein analyte(s) is present in the sample, binding occurs between the protein analyte(s) and the labelled reagent(s), followed by further migration of the co-associated analyte(s)- labelled-reagent(s) along the membrane.
  • a test line containing a capture reagent(s) with affinity for the target protein analyte(s) e.g.
  • the same antibody or antibodies but without the labelling captures the co-associated analyte(s)-labelled-reagent(s) i.e. in a manner akin to a ‘sandwich’ assay.
  • the labelling means associated with the migrated reagent(s) provides a detectable output. For example, a visual line is formed in the case of gold particles, thus confirming the presence of the target protein analyte(s).
  • LFDs additionally also include a control line that confirms the sample has passed along the membrane, and that the labelled reagent(s) are active.
  • the protein analytes in question are in particular the biomarkers comprising the biomarker signature identified from the 22-protein panel of Table 1.
  • each LFD may be split into a plurality of strips (or lanes) to accommodate the number of markers i.e. a multiplex assay.
  • each LFD assay may be split into four strips, such that ten biomarkers could be accommodated by three LFD assays.
  • Utilising labels with different output wavelengths would enable measuring the level of each biomarkers on a multiplexed LFD assay.
  • the test element is a protein array.
  • the kit in an ELISA-based approach. Both approaches employ reagents immobilised to a surface, wherein the static reagents are capable of capturing a target protein analyte(s). Further labelled reagent can be bound to the captured target protein analyte(s), ensuring a detectable (i.e. quantitative) output can be analysed to confirm the present/level of protein analyte(s) in a sample.
  • the LFD may comprise a filter to ensure particulate material does not block the LFD membrane.
  • the filter may remove red blood cells such that patient serum can be interrogated to measure the level of each biomarker comprising a biomarker signature to assess for infection and/or organ dysfunction and/or sepsis.
  • the kit may further comprise a detector or reader capable of providing a quantitative measurement of the level of biomarkers in the biomarker signature.
  • the kit further comprises an anticoagulant.
  • an anticoagulant This ensures that a blood sample taken from a patient does not clot, potentially interfering with the level of biomarkers comprising a biomarker signature that may be present in the blood sample.
  • the invention provides a system for implementing the first aspect, second aspect, third aspect or fourth aspect, the system comprising: a. the kit of the sixth aspect; b. a detector for monitoring, measuring or detecting the individual levels of the protein biomarkers; and c. a computer processor configured to analyse data produced by the detector.
  • Operation of the system by a user can provide an output in relation to predicting, diagnosing or monitoring sepsis in a patient, or the responsiveness of the patient to treatment with an antimicrobial agent(s) and/or immunosuppressive agent(s), or selecting a therapeutic agent(s) and/or immunosuppressive agent(s) for treatment of sepsis.
  • the system of the seventh aspect may be computer-implemented to determine individual levels of biomarkers, representing a biomarker signature, in a sample. This would be particularly advantageous if such biomarker signature analysis is increasingly complex due to measuring a plurality of samples from a patient (i.e. taken at a plurality of time points), or measuring a plurality of samples taken from different patients.
  • Such a computer-implemented system could enable a positive or negative readout in terms of whether infection, and/or organ dysfunction, and/or sepsis is likely to develop (or worsen/lessen).
  • the kit or system could at least provide an indication of the likelihood of sepsis developing.
  • the invention also provides a method according to the first aspect, second aspect, third aspect and fourth aspect, a kit according to the sixth aspect, or system according to the seventh aspect, wherein the patient is a post-surgical patient, an immunocompromised individual, an intensive-care patient or a burn patient.
  • kit and system aspects may include control elements (e.g. control biomarkers and respective control labelled reagents) to help validate the output of said methods, kit or system.
  • control elements e.g. control biomarkers and respective control labelled reagents
  • the invention may comprise, consist essentially of, or consist of any feature or combination of features.
  • Figure 1 is an illustration depicting the rationale for sample selection, including the selection of control samples, and the matching with sepsis patient samples;
  • Figure 2 is a graph of the proportion of samples within the sepsis group outside the 90% quantiles of the SIRS and comparator groups for each of 718 protein analytes across time points;
  • Figure 3 is a dendrogram of the relatedness of protein analytes by cluster analysis.
  • the invention provides a method for analysing a biological sample, obtained from a patient, to assess the patient for sepsis, the method comprising the steps of: a. determining in the biological sample individual levels of biomarkers representing a protein biomarker signature; and b.
  • the biomarkers of the protein biomarker signature comprises at least four biomarkers from a list consisting of CCL-16, CD28, CD244, FGF21, GALNT3, GT, IL-18BP, JAM-A, LDL-R, LILRB5, LTBR, MCP-2, MMP-1 , NUCB2, SIGLEC10, TNF-R1, TNF-R2, TNFRSF10A, TNFRSF11A, TNFRSF14, TRAILR2 and UPAR.
  • HIV HIV, Hepatitis A, B or C
  • Blood samples were collected according to an ethically-approved protocol. Briefly, a 4 ml aliquot of patient blood was separately collected into a sterile serum separation tube. Following centrifugation, the serum was pipetted into an appropriately sized vial. All samples were then stored at -20°C and eventually transported on dry ice. Blood collection occurred once between 1 and 7 days before surgery and then once daily on each day post-surgery. Post-operative blood collection was stopped after the patient was discharged from hospital, or after 7 days post-surgery, or once the clinician had confirmed sepsis. Additional patient information (e.g. daily patient metrics, type of surgery and microbiology results) was captured using a bespoke database provided by ItemTracker, UK. All samples collected from patients were stored at Dstl in suitably alarmed freezers that were monitored daily.
  • a Clinical Advisory Panel comprising experts from across the UK and Germany, was tasked to provide a definitive judgement on whether a patient had developed sepsis according to the Sepsis-2 criteria.
  • CAP Clinical Advisory Panel
  • all relevant patient data was presented to them and a silent vote was conducted.
  • the results of this process were captured by a facilitator whose role was to ensure that no conferring had occurred and record the clinical opinion. If a consensus of opinion for a sepsis patient was achieved, then the clinicians were asked to indicate the day of sepsis diagnosis (without conferring). If consensus was again achieved then the facilitator moved to the next patient. If no consensus was reached, either for patient outcome or on day of sepsis diagnosis, then clinicians were allowed to discuss the reasons for their mixed opinions.
  • the equivalent post-operative blood sample from the age/gender/procedure-matched comparator was used.
  • the blood samples taken from days 4, 5 and 6 post surgery were used for comparison, acting as Day -3, -2 and -1 controls.
  • the process of matching the pre-symptomatic blood samples of patients who went on to develop sepsis with their most appropriate post-operative comparators was then repeated for all sepsis patients.
  • Table 2 summarises a series of top-level characteristics for patients involved in the study.
  • Table 2 Summary of patient ages, gender, delay for sepsis and types of surgery
  • Graphs were generated using the software Graphpad PRISM V8.0. Statistical analysis was performed using IBM SPSS V26.0. NPX data from the three panels were collated into a single file. Where proteins had been investigated in more than one panel, the mean value was taken. Some missing data was replaced using a regression based with random effect method of imputation. These missing values principally consisted of one sample in certain analytes. All data NPX was used regardless of whether the values were within the limits of quantification or whether all quality controls were passed.
  • the top 40 protein analytes at time of diagnosis and 1 day prior were selected (i.e. the protein analytes outside the 90% quantiles of the SIRS and control samples in the most ‘sepsis’ samples. These protein analytes were subjected to stepwise cluster using Pearson’s correlations. A dendrogram was then used to select protein analytes that were most unrelated. The “left-most” members of each cluster at different levels of similarity were selected because these represented the least related protein to the next cluster. The ability of different groups of protein analytes to predict sepsis was assessed using multilayer perceptron neutral networks. (Other algorithms that can manage heterogeneity, such as random forests are also suitable. Conversely, linear discriminant analysis would be less useful for the same reason).
  • the SPSS adaptive algorithm was used to fine-tune the methodology of each analysis.
  • the neural nets were trained ten times using 70% of the data at both time of diagnosis and 1 day prior. The same 70% of individuals was used at both time points. For each of the iterations, a random selection program was generated that ensured that the same 70% was used at both time points. The other 30% and other time points were used to predict efficacy. Efficacy was estimated and compared by Receiver Operator Characteristics (ROC) analysis of the membership estimates and the AUC of the ROC curve.
  • ROC Receiver Operator Characteristics
  • the O-link output generated data for 718 protein analytes.
  • a metric was needed for rapid down-selection of target protein analytes where the greatest proportion of readings in the sepsis group were outside the normal range of the two control data sets (comparator controls and SIRS).
  • the strategy devised included first calculating the 5 th and 95 th percentiles of the two control groups at each time point and then using logic functions to numerate the number of sepsis readings at the same time point that were outside this range. The greatest number of sepsis samples with specific proteins outside this 90% range were considered most likely to be useful in sepsis diagnosis.
  • Protein biomarker signatures containing between four and ten proteins showed evidence for predictive power when visualised individually. Importantly, the proteins within a biomarker signature correlated with each other very poorly. In this respect, it was reasonable to assume that these protein analytes will complement each other well in a multiple protein analyte diagnostic. Tumour Necrosis Factor Receptor 1 (TNF-R1) was part of a large cluster. In this respect, alternative protein analytes might be used with little effect and the fact that these alternatives are found in similar concentrations can also be visualised. Similarly, CD28 is similarly expressed to CD244.
  • Table 3 describes the predictive efficacy, described in terms of AUC, of a series of biomarker subsets produced from the list of 22 proteins down-selected for the biomarker signature (SD: standard deviation).
  • SD standard deviation
  • Table 3 Predictive efficacy for sepsis of a series of biomarker signatures derived from 22 down-selected proteins
  • the labelled reagent(s) may include element(s) capable of specifically binding to at least one of the proteins in a protein biomarker signature according to the present invention, wherein the element(s) may be capable of being linked or associated with a labelling means during application of the method, kit or system that allows for identification of the presence of the protein.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des biomarqueurs protéiques représentant des signatures de biomarqueurs protéiques pour évaluer un patient qui peut développer une sepsie, ou qui peut avoir développé une sepsie. L'invention concerne en particulier des procédés d'évaluation ou de surveillance par rapport au diagnostic, à la prédiction ou à la progression d'une sepsie chez un patient, ainsi que la réactivité au traitement de la septicémie ou la sélection d'agents appropriés pour ledit traitement. L'invention concerne également l'utilisation de biomarqueurs protéiques représentant des signatures de biomarqueurs protéiques pour la septicémie, et des kits et un système associés.
EP21736646.7A 2020-06-19 2021-06-17 Procédés et utilisations associées, kits et système d'évaluation de la septicémie Pending EP4168806A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2009401.7A GB2596142B (en) 2020-06-19 2020-06-19 Methods and associated uses, kits and systems for assessing sepsis
PCT/GB2021/000074 WO2021255408A2 (fr) 2020-06-19 2021-06-17 Procédés et utilisations associées, kits et système d'évaluation de la septicémie

Publications (1)

Publication Number Publication Date
EP4168806A2 true EP4168806A2 (fr) 2023-04-26

Family

ID=71838357

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21736646.7A Pending EP4168806A2 (fr) 2020-06-19 2021-06-17 Procédés et utilisations associées, kits et système d'évaluation de la septicémie

Country Status (4)

Country Link
US (1) US20230228765A1 (fr)
EP (1) EP4168806A2 (fr)
GB (1) GB2596142B (fr)
WO (1) WO2021255408A2 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1611255A2 (fr) * 2003-04-02 2006-01-04 SIRS-Lab GmbH Procede pour depister des etats infectieux generalises (sirs), des sepsis, des etats de type sepsis et des infections systemiques
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
EP1869463A4 (fr) * 2005-04-15 2010-05-05 Becton Dickinson Co Diagnostic d'une sepsie
CA2624569A1 (fr) * 2005-10-03 2007-04-12 Biosite Incorporated Methodes et compositions utiles dans le diagnostic et/ou le pronostic des syndromes de reponse inflammatoire systemique
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
WO2013152047A1 (fr) * 2012-04-02 2013-10-10 Astute Medical, Inc. Procédés et compositions de diagnostic et de pronostic d'un sepsis
EA201790696A1 (ru) * 2014-10-20 2017-10-31 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
GB201616557D0 (en) * 2016-09-29 2016-11-16 Secretary Of State For Health The Assay for distinguishing between sepsis and systemic inflammatory response syndrome

Also Published As

Publication number Publication date
GB2596142A (en) 2021-12-22
WO2021255408A2 (fr) 2021-12-23
US20230228765A1 (en) 2023-07-20
GB202009401D0 (en) 2020-08-05
WO2021255408A3 (fr) 2022-02-17
GB2596142B (en) 2023-11-29

Similar Documents

Publication Publication Date Title
US11016103B2 (en) Predicting mortality and detecting severe disease
JP6595984B2 (ja) 腎機能に関連付けられるバイオマーカーおよびそれを使用する方法
US20170140122A1 (en) Methods and compositions for monitoring heart failure
EP1888765A2 (fr) Procédés et compositions du diagnostic de maladie thrombo-embolitique veineuse
JP6440719B2 (ja) 腎疾患のバイオマーカー
CN109844526A (zh) 使用胰岛素样生长因子结合蛋白7和金属蛋白酶2的组织抑制剂管理急性肾损伤
WO2013006629A1 (fr) Procédés et compositions permettant de définir un degré de vraisemblance d'évolution d'une lésion rénale aiguë
WO2012074888A2 (fr) Procédés et compositions pour le diagnostic et la prédiction du risque d'insuffisance cardiaque
Taghvaei et al. Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis
WO2012033999A2 (fr) Marqueurs biologiques permettant de prévoir des pathologies rénales et glomérulaires
JP2019525184A (ja) 臓器障害を示すマーカーとしてのヒストンおよび／またはｐｒｏＡＤＭ
WO2013096740A1 (fr) Procédés et compositions destinés à attribuer une probabilité de progression de maladie rénale chronique
Swolinsky et al. Plasma NGAL levels in stable kidney transplant recipients and the risk of allograft loss
US20230228765A1 (en) Methods and associated uses, kits and system for assessing sepsis
JP2020051911A (ja) 心不全マーカー
US20240168038A1 (en) Method of determining prognosis of chronic kidney disease
Fleming et al. FORM-2C (Frequency of Renal Monitoring–Creatinine and Cystatin C): an observational cohort study of primary care patients with reduced eGFR

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221206

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)